CN113056480B - 人源化抗N截短淀粉样β单克隆抗体 - Google Patents

人源化抗N截短淀粉样β单克隆抗体 Download PDF

Info

Publication number
CN113056480B
CN113056480B CN201980065883.5A CN201980065883A CN113056480B CN 113056480 B CN113056480 B CN 113056480B CN 201980065883 A CN201980065883 A CN 201980065883A CN 113056480 B CN113056480 B CN 113056480B
Authority
CN
China
Prior art keywords
ser
gly
thr
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980065883.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN113056480A (zh
Inventor
T·拜耳
P·巴克拉尼亚
S·戴维斯
A·布朗
C·姆帕曼加
D·马修斯
M·卡尔
G·霍尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Agco
George Auguste Gottingen University Public Law University Medical Foundation
Original Assignee
Life Agco
George Auguste Gottingen University Public Law University Medical Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Agco, George Auguste Gottingen University Public Law University Medical Foundation filed Critical Life Agco
Publication of CN113056480A publication Critical patent/CN113056480A/zh
Application granted granted Critical
Publication of CN113056480B publication Critical patent/CN113056480B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980065883.5A 2018-10-04 2019-10-02 人源化抗N截短淀粉样β单克隆抗体 Active CN113056480B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1816210.7 2018-10-04
GB201816210 2018-10-04
PCT/EP2019/076772 WO2020070225A1 (en) 2018-10-04 2019-10-02 Humanised anti-n-truncated amyloid beta monoclonal antibody

Publications (2)

Publication Number Publication Date
CN113056480A CN113056480A (zh) 2021-06-29
CN113056480B true CN113056480B (zh) 2025-06-13

Family

ID=68136417

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980065883.5A Active CN113056480B (zh) 2018-10-04 2019-10-02 人源化抗N截短淀粉样β单克隆抗体

Country Status (13)

Country Link
US (1) US12297261B2 (https=)
EP (1) EP3861023A1 (https=)
JP (1) JP7610515B2 (https=)
KR (1) KR102862077B1 (https=)
CN (1) CN113056480B (https=)
AU (1) AU2019354714A1 (https=)
BR (1) BR112021006153A2 (https=)
CA (1) CA3114669A1 (https=)
EA (1) EA202190954A1 (https=)
IL (1) IL281979B2 (https=)
MX (1) MX2021003867A (https=)
SG (1) SG11202102765RA (https=)
WO (1) WO2020070225A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4118111A1 (en) 2020-03-10 2023-01-18 LifeArc Cyclic peptides
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
PE20252307A1 (es) 2022-12-22 2025-09-22 Bioarctic Ab Anticuerpo que se une a abetape3
WO2025262228A1 (en) 2024-06-20 2025-12-26 Bioarctic Ab Bispecific binding molecule

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111518206A (zh) * 2019-02-01 2020-08-11 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
CN115698060A (zh) * 2020-03-10 2023-02-03 生命爱科 环肽

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US474900A (en) 1892-05-17 William byrnes
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
WO2008081008A1 (en) * 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
MY155144A (en) 2007-10-29 2015-09-15 Inst Nat Sante Rech Med NEW ANTIBODIES SPECIFIC OF THE ß-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS
WO2011151076A2 (en) * 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
EP2847217B1 (en) 2012-05-10 2017-10-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST OLIGOMERS of Amyloid beta
WO2015173133A1 (en) 2014-05-12 2015-11-19 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
CA2992386A1 (en) * 2015-07-16 2017-01-19 Probiodrug Ag Humanized antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111518206A (zh) * 2019-02-01 2020-08-11 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
CN115698060A (zh) * 2020-03-10 2023-02-03 生命爱科 环肽

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Discovery of a novel pseudoβ-hairpin structure of N-truncated amyloid-βfor use as a vaccine against Alzheimer’s disease;Preeti Bakrania 等;《Molecular Psychiatry》;20211115;840-848 *

Also Published As

Publication number Publication date
CA3114669A1 (en) 2020-04-09
JP7610515B2 (ja) 2025-01-08
BR112021006153A2 (pt) 2021-06-29
MX2021003867A (es) 2021-09-08
JP2022513331A (ja) 2022-02-07
EA202190954A1 (ru) 2021-06-29
US20210347867A1 (en) 2021-11-11
EP3861023A1 (en) 2021-08-11
CN113056480A (zh) 2021-06-29
AU2019354714A1 (en) 2021-04-29
SG11202102765RA (en) 2021-04-29
KR102862077B1 (ko) 2025-09-18
IL281979B2 (en) 2025-09-01
KR20210080400A (ko) 2021-06-30
US12297261B2 (en) 2025-05-13
IL281979B1 (en) 2025-05-01
IL281979A (en) 2021-05-31
US20230203140A9 (en) 2023-06-29
WO2020070225A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
CN113056480B (zh) 人源化抗N截短淀粉样β单克隆抗体
TWI754157B (zh) 抗ｔｉｇｉｔ抗體及其用途
JP5980249B2 (ja) 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法
EP3344654B1 (en) Anti-lag-3 antibodies
TWI823895B (zh) 抗b7-h4抗體、其抗原結合片段及其醫藥用途
TWI419704B (zh) 預防及治療與補體相關之眼部病症
AU2019202447B2 (en) Binding molecules specific for il-21 and uses thereof
WO2018095428A1 (zh) Cd47抗体、其抗原结合片段及其医药用途
CN111995681A (zh) 抗tigit的抗体、其制备方法和应用
JP7093794B2 (ja) 免疫関連障害のための抗体－サイトカイングラフト化タンパク質及び使用方法
US20180037667A1 (en) Anti-factor b antibodies and their uses
TW202035455A (zh) 抗ｏｘ４０抗體、其抗原結合片段及其醫藥用途
JP2025041747A (ja) ヒト化抗ｉｌ１７ｂｒ抗体
WO2019242619A1 (zh) 全人源的抗lag-3抗体及其应用
JP2004536605A (ja) インターロイキン１β抗体
CN117015553A (zh) 包含白细胞介素-18结合蛋白和抗血清白蛋白的抗原结合片段的重组融合蛋白及其组合物和用途
CN1835976B (zh) 无糖基抗-cd154(cd40配体)抗体及其用途
JP2025115976A (ja) Ｔｌ１ａに特異的に結合できる抗体及びその使用
HK40042152B (zh) 抗tigit抗体及其用途
HK1256116B (en) Anti-lag-3 antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20391209